Alentis Therapeutics, a groundbreaking clinical-stage biotechnology firm at the forefront of developing pioneering therapies targeting Claudin-1 (CLDN1) for the treatment of tumors and organ fibrosis, has successfully raised $167.6 million in its latest funding round. This significant investment will accelerate Alentis' mission to develop first-in-class antibodies and antibody-drug conjugates (ADCs) focused on the innovative targeting of CLDN1—an unexploited yet critical target in the pathology of solid tumors and fibrotic diseases. Alentis stands out as the only company fiercely dedicated to advancing treatments for CLDN1-related solid cancers and organ fibrosis, signalling a new era in therapeutic options for these challenging conditions.
The funds raised will primarily support the ongoing development of Alentis' promising portfolio, including the lead oncology asset, ALE.C04, designed to reprogram the tumor microenvironment (TME) and enhance the efficacy of treatment against solid tumors. In addition, the funding will bolster the advancement of ALE.F02, currently in Phase 1 clinical trials, which aims to reverse organ fibrosis associated with conditions in the kidney, lung, and liver. Established in 2019 under the pioneering research of Prof. Thomas Baumert at the University of Strasbourg, Alentis operates from its base in Basel’s pharma-biotech hub, emphasizing its commitment to innovation and transformative healthcare solutions. This new infusion of capital represents a decisive step toward unlocking the full potential of Alentis’ cutting-edge therapies, ultimately aiming to improve the lives of patients facing debilitating diseases. For further information, please visit www.alentis.ch or reach out at info@alentis.ch.
